相关实验视频

Updated: Jan 13, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

贝瓦西祖马布在卵巢癌:临床数据和预测和预后生物标志物

Maria Rosaria Lamia^1,2, Erica Perri^2,3, Gustavo Baldassarre⁴

¹Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.

Clinical and translational medicine

|January 10, 2026

概括

贝瓦西祖马布是卵巢癌 (OC) 的关键治疗方法,通过向血管生成来抑制瘤生长. 然而,预测患者反应需要经过验证的生物标志物来有效指导个性化治疗.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

血管新生是由低氧下的VEGF/VEGFR信号驱动的,对于卵巢癌 (OC) 的进展和免疫规避至关重要.
同源复合缺陷 (HRD) 与增加的瘤缺氧和OC中的亲血管性信号相关.
抑制VEGF通路提供了与PARP抑制剂 (PARPi) 和免疫检查点抑制剂的潜在协同作用.

研究的目的:

审查贝瓦西祖马布在卵巢癌 (OC) 管理中的作用.
讨论将抗血管生成疗法与PARPi和免疫疗法结合使用的生物学理由.
要突出在OC中对贝瓦西祖马布反应的预测生物标志物的未满足需求.

主要方法:

对bevacizumab在一线,复发性敏感性和抗性OC的临床疗效数据的审查.
分析研究的生物标志物,包括血管性因素,VEGF-A异型和转录亚型.
对MITO16A/MaNGO OV-2计划的翻译发现进行了检查.

主要成果:

贝瓦西祖马布证明了作为维持疗法和在复发性OC设置中的临床疗效.
许多生物标志物 (血管性因素,HRD状态,微RNA) 已被研究,但没有一个被验证可以预测贝瓦西祖马布的益处.
生物标志物验证的挑战包括试验标准化和外部验证.

结论:

贝瓦西祖马布是OC治疗的组成部分,向瘤血管生成.
验证的预测生物标志物对于优化贝瓦西祖马布的临床应用至关重要.
未来的研究应该专注于生物标志物驱动的试验,整合多组数据和精准医学的机器学习.

关键词:

在 PARP 抑制剂的使用中.在VEGF中,VEGF是VEGF.血管新生是因为血管新生.这是bevacizumab的治疗方法.同类重组缺陷 (HRD)卵巢癌是发生在卵巢的癌症.预测性的生物标志物预后生物标志物预后生物标志物

更多相关视频

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...